Bristol Myers Squibb invests in Nvidia's latest computing system to accelerate drug discovery and development operations.
Bristol Myers Squibb is purchasing the latest-generation computing system from Nvidia to enhance its artificial intelligence capabilities across drug discovery and development. The pharmaceutical giant will be the first life sciences company to adopt an Nvidia DGX SuperPOD based on the Vera Rubin architecture. The new system provides researchers with a unified AI platform to run predictions and train models across the full drug discovery pipeline. Robert Plenge, chief research officer at Bristol Myers Squibb, stated that the new capabilities will allow the company to cycle through dozens of potential drug candidates early in the development process. Additionally, Greg Meyers, the company's chief digital and technology officer, noted that the investment addresses rapidly growing computing demands while providing 10 times more compute capacity per watt spent. By integrating these systems, the company aims to translate abstract AI potential into measurable impact. The infrastructure allows scientists to focus on high-value scientific decisions rather than the logistics of resource management, ultimately aiming to reduce the time required to develop new medicines for clinical trials.